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a b s t r a c t
The recent emergence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV), nearly a decade
after the Severe Acute Respiratory Syndrome (SARS) CoV, highlights the importance of understanding
and developing therapeutic treatment for current and emergent CoVs. This manuscript explores the role
of NSP16, a 2′O-methyl-transferase (2′O-MTase), in CoV infection and the host immune response. The
review highlights conserved motifs, required interaction partners, as well as the attenuation of NSP16






identifies a number of approaches to exploit this understanding for therapeutic treatment and the data
clearly illustrate the importance of NSP16 2′O-MTase activity for CoV infection and pathogenesis.DA5
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Coronaviruses represent important human pathogens that have
merged multiple times from zoonotic reservoirs over the past
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ttp://dx.doi.org/10.1016/j.virusres.2014.09.009few centuries (Becker et al., 2008; Graham et al., 2013; Li
et al., 2005; Nicholls et al., 2003; Perlman and Netland, 2009).
In the aftermath of severe acute respiratory syndrome corona-
virus (SARS-CoV) emergence in 2003, substantial efforts were
made to improve our understanding of CoV infection and patho-
genesis in order to develop novel therapeutics for current and
future CoV mediated outbreaks (Perlman and Netland, 2009).
Despite significant advances over the past decade, broadly effec-
tive treatments for SARS-CoV remain elusive. Coupled with the






























































MERS) CoV in 2012 (Corman et al., 2012; Josset et al., 2013)
nd a virulent strain of porcine epidemic diarrhea virus (PEDV)
Huang et al., 2013), the lack of progress underscores the con-
inued need to study and develop treatment for this family of
iruses.
As the SARS-CoV outbreak progressed, computational models
redicted a number of enzymatic functions conserved in the viral
oly-protein including a conserved 2′O-methyl-transferase activ-
ty (2′O-MTase) for CoV non-structural protein 16 (NSP16) (Snijder
t al., 2003). While unknown at the time, subsequent immunity
esearch revealed a role for 2′O-methylation of viral mRNA in dis-
inguishing between self/non-self (Daffis et al., 2010; Zust et al.,
011). The presence of these host and virus effectors suggested the
mportance of 2′O-methylation as a virulence determinant during
oV infection. In this review, we examine NSP16 interaction part-
ers and activity as well as the factors that mediate host responses.
n addition, the manuscript explores approaches to exploit these
athways for therapeutic treatment of both current and emer-
ent disease. Overall, the review seeks to update the current state
f the CoV NSP16 field and possibilities for future therapeutics
ased on targeting 2′O-MTase activity and corresponding immune
esponses.
. mRNA capping and host recognition
Overcoming the host immune response is paramount to the
uccess of any viral infection. Since the immune response is pred-
cated on recognition, viruses have evolved means to disrupt host
ensing through either direct antagonism of pathway components
r molecular mimicry of host processes (Decroly et al., 2012).
n important example of the latter is the duplication of cap-
ing elements for viral mRNAs (Decroly et al., 2012). Eukaryotic
osts utilize a 5′-terminal capping system to promote efficient
uclear export, robust translation, and enhanced stability of host
RNA. In addition, mRNA capping structure also helps to dis-
inguish between self/non-self RNA and can lead to initiation
f the host immune response. In recent years, unprotected 5′-
riphosphates on nascent RNA (Fig. 1A) has been identified as
art of the recognition trigger for host sensor molecule retinoic
cid inducible gene I (RIG-I) leading to down stream type I IFN
nduction (Hornung et al., 2006; Myong et al., 2009). Similarly,
oth IFN-induced protein with tetratricopeptide repeats (IFIT)
and IFIT5, highly induced interferon-stimulated genes (ISGs),
lso bind exposed 5′-triphosphate on viral RNA, interfering with
heir activity through competition with EIF4E (Diamond, 2014;
ichlmair et al., 2011; Habjan et al., 2013). Triphosphate cleav-
ge and addition of the 7-methylguanosine cap effectively protect
ost mRNA from this particular targeting (Fig. 1B–D). However,
nmethylated 2′O on the ribose of cap-0 RNA has also been
dentified as a pathogen associated molecular pattern (PAMP);
ecognized by host sensor molecule Melanoma Differentiation-
ssociated protein 5 (MDA5) as well the effector IFIT family,
he absence of 2′O-methylation on viral RNA induces a more
obust type I IFN response that attenuates viral replication and
nfection in vitro and in vivo (Fig. 1E) (Daffis et al., 2010; Zust
t al., 2011). In contrast, viral mRNA maintaining both the 7-
ethylguanosine cap and 2′O-methylation (caps 1 and 2, Fig. 1F)
emains viable to levels similar to host mRNA. Together, recogni-
ion of these moieties and the subsequent host response indicate
he importance of mRNA capping restrictions as a barrier to viral
nfection. These findings also raise the possibility that capping
ctivities may preferentially function as a defense mechanism
gainst cell intrinsic antiviral effectors, suggesting the possibility
hat viral mRNA are preferentially translated by cap-independent
echanisms.3. Coronavirus capping
Naturally, viruses have evolved a variety of mechanisms to over-
come these capping restrictions. For viruses that replicate within
the nucleus including most DNA viruses and retroviruses, using
the host capping machinery provides the primary means of protec-
ting mRNA from restriction (Decroly et al., 2012). Similarly, other
viral families including orthomyxoviruses, arenaviruses, and bun-
yaviruses, employ “cap snatching” to excise cap structures from
early host RNAs and incorporated them into nascent viral RNAs.
Finally, many viral families encode their own capping machin-
ery that either mimics the sequential eukaryotic approach or an
alternative approach to effectively maintain translation and block
aspects of host immune recognition. Examples of the later approach
include VpG-like viral proteins that mimic cap structures like picor-
naviruses and caliciviruses that bind 5′ viral RNA acting as a cap
(Decroly et al., 2012); similarly, RNA secondary structure including
internal ribosome entry sites (IRES) elements permit translation
of viral RNA and may offer minor protection from host recogni-
tion (Hyde et al., 2014). Importantly, a significant portion of viruses
encode their own viral capping proteins that directly copy the host
machinery, making it indistinguishable from host mRNA and neu-
tralizing an important barrier to viral infection.
For coronaviruses, a series of highly conserved non-structural
proteins (NSPs) have been identified in capping viral RNA. Detailed
reports have identified or predicted roles for NSP13 (Ivanov et al.,
2004; Ivanov and Ziebuhr, 2004), NSP14 (Chen et al., 2009), and
most recently, the NSP10/NSP16 complex (Bouvet et al., 2010; Chen
et al., 2011; Debarnot et al., 2011; Decroly et al., 2008, 2011; Lugari
et al., 2010) in capping of CoV RNA. Similar to the host process,
the capping is believed to be initiated by a RNA phosphatase that
removes a phosphate group from the nascent mRNA (Fig. 1A); for
CoVs, this process has been attributed to the 5′–3′ helicase/NTPase
NSP13, although not yet confirmed by experimental examination
(Fig. 1B) (Snijder et al., 2003). Thereafter, an undetermined host
or viral guanyly transferase (GTase) mediates cleavage of GTP to
GMP and covalent attachment to the diphosphate linked mRNA
(Fig. 1C). Next, NSP14, an SAM-dependent MTase, facilitates the
addition of a methyl group to the guanosine at N7, producing a
viral mRNA cap-0 structure (Fig. 1D). Following this step, the viral
RNA is effectively protected from RIG-I recognition of the free 5′
triphosphate; however, absent 2′O-methylation, the viral mRNA
will still trigger the sensor MDA5 and IFIT effectors (Fig. 1E). The
mRNA cap for CoVs is completed by NSP16, an SAM-dependent
nucleoside-2′O-methyl-transferase, that ensures formation of a
protective cap-1 structure that prevent recognition by either MDA5
or IFIT proteins (Fig. 1F). Finally, the NSP16/NSP10 complex finishes
CoV capping process permitting viral infection with reduced host
recognition.
4. Structural conservation and catalytic tetrad
CoV 2′O-MTase belongs to the RrmJ/fibrillarin superfamily of
ribose 2′O-methyl-transferases conserved in a number of host
cellular homologues as well as viral orthologs in Flaviviruses,
Alphaviruses, and Nidoviruses (Feder et al., 2003). This family of
proteins catalyzes the transfer of S-adenosylmethionine (SAM)
methyl group to methyl acceptors and relies on a conserved
K-D-K-E tetrad within the substrate binding pocket for activity.
Substitution at any of three residues (K-D-K) resulted in ablation
of catalytic activity (Feder et al., 2003). In addition to the tetrad,
the canonical members of this enzyme family including catechol
O-MTase, maintain a conserved structural motif of seven-stranded
B-sheets flanked by three alpha helices on each side that consti-
tute both the acceptor substrate and SAM-binding domains (Martin
Fig. 1. Viral mRNA capping. (A) Nascent mRNA incorporates an unprotected 5′-triphosphate that can be recognized by both immune sensor RIG-I and ISG IFIT molecules
if left unmodified. (B) Triphosphate cleavage initiates the first step in mRNA capping and is predicted to be mediated by CoV NSP13, a 5′–3′ helicase/RTPase. (C) Guanyly
























n SAM dependent methyl-transferase (MTase), methylates the N7 guanosine, resu
till stimulates MDA5 and IFIT proteins via the unprotected 2′OH. NSP16, a 2′O-MTas
ails to induced either MDA or IFIT proteins, permitting robust viral replication in th
nd McMillan, 2002). These structural and catalytic elements are
equired for SAM-dependent MTase activity.
For CoV NSP16, the requirement for a viral co-factor, NSP10,
istinguishes them from the more canonical 2′O-MTase family
embers. Early computational studies had predicted NSP16 as a
′O-MTase (Snijder et al., 2003; von Grotthuss et al., 2003) and sub-
equent work confirmed a low, but present 2′O-MTase activity with
eline CoV (FCoV) NSP16 (Decroly et al., 2008). However, recombi-
ant SARS-CoV NSP16 failed to replicate a similar activity despite
oteworthy homology with FCoV NSP16. Examination of yeast-
wo hybrid screens later revealed a strong interaction between
SP16 and NSP10 suggesting a possible role in capping (Imbert
t al., 2008; Pan et al., 2008). Further work demonstrated co-
xpression of NSP10 with NSP16 permitted SARS-CoV 2′O-MTase
ctivity in the presence of already capped N7-methylated RNA
Bouvet et al., 2010). Similarly, co-expression permitted capture
f a purified NSP16-NSP10 crystal structure unstable with NSP16
lone (Decroly et al., 2011). Based on this structure, the authors
ostulated the absence of two the flanking alpha helices resulted
n a less stable CoV 2′O-MTase than canonical family members; the
ddition of NSP10 potentially alleviates this instability permittingn cap-0 structure. (E) The cap-0 structure, while protected from RIG-I recognition,
ognizes and binds to cap-0 CoV RNA, resulting in methylation. (F) Cap-1 viral mRNA
ence of the innate immune response.
2′O-MTase activity to occurs. Additional structural and biochem-
ical analysis suggested that NSP10 binding within this region
provided support for SAM-binding of NSP16 as well as extend-
ing the RNA binding groove of the complex (Chen et al., 2011).
Overall, the data demonstrates the complex interaction between
NSP16 and NSP10 that is required for stability and 2′O-MTase
activity.
5. NSP16 conservation, CoV mutants, and attenuation
The amino acid sequence of NSP16 is highly conserved across
the entire CoV family, suggesting similar structural domains and
functional activities. This conservation, illustrated in the structural
similarities between SARS-CoV and MERS-CoV NSP16/NSP10 com-
plexes (Fig. 2), indicate mutations that ablate or alter activity would
be conserved across the entire viral family, resulting in similar
phenotypic mutants. Therefore, therapeutics and treatments that
target the activity and function of NSP16/NSP10 may prove effec-
tive against previous strain like SARS-CoV and HCoV 229E, as well
as emergent viruses like MERS-CoV and PEDV.
Fig. 2. Conservation of CoV NSP16. Overlay of NSP16 structures from SARS-CoV
(black) and emergent MERS-CoV (gray). The conserved KDKE motif is represented in
the inset for SARS-CoV (primary colors) and MERS-CoV (pastel colors). Also shown,
required NSP10 scaffold for SARS-CoV (pink) and MERS-CoV (orange). Homology





































oolkit. The known crystal structure for the NSP10/16 complex (3R24 in the RCSB
rotein data bank) was used as the template structure (Chen et al., 2011). Homology
odels were then manipulated using MacPyMol.
The initial attempts to alter NSP16 function focused on deletion
nd the conserved KDKE tetrad (Chen et al., 2011). Deletion of the
SP16 coding sequence blocked RNA synthesis; similarly, deletion
f up stream components (Exonuclease-NSP14 and N-terminal zinc
inding domain endoribonuclease-NSP15) also ablated viral repli-
ation and RNA synthesis (Almazan et al., 2006). However, mutation
t D130A (D6905A) within the conserved KDKE tetrad of NSP16
esulted in a severely attenuated, but partially viable mutant virus.
n addition, temperature sensitive mutants in mouse hepatitis virus
MHV) established a role for NSP16 in synthesis or stability of pos-
tive strand synthesis (Sawicki et al., 2005). Together, these early
tudies implied a critical role for NSP16 in the CoV life cycle.
However, these results may have been influenced by the
nderlying immune response captured by the cell cultures sys-
em. Subsequent attempts with HCoV 229E, MHV, and SARS-CoV
ere able to generate mutants that reduced or ablated NSP16
ctivity, but retain robust viral replication in vitro (Menachery
t al., 2014b; Zust et al., 2011). Substitution of aspartic acid
or alanine (D129A) within the KDKE motif of HCoV 229E
esulted in ablation of 2′O-MTase activity; importantly, the
29E mutant was attenuated in fibroblast multistep growth
urves, induced more type I IFN in macrophages, and was more
ensitive to IFN pretreatment that WT 229E (Zust et al., 2011).
owever, the same mutation (D130A) in MHV resulted in resulted
n minimal attenuation 17Cl1 murine fibroblasts, but robust repli-
ation deficits and increased type I IFN induction in macrophages,
uggesting a cell type specific contribution to NSP16 attenuation.
otably, NSP16 mutations that targeted the putative cap-0 bind-
ng site (MHV-Y14A) maintained partial 2′O-MTase activity, had
educed immune induction, and minimal replication attenuation
n macrophages compared to the D130A mutant. Overall, the data
uggested that NSP16 activity is required for efficient replication in
ertain, immune competent cells.
For SARS-CoV, mutations in NSP16 also target the conserved
DKE motif; focusing on the trio required for catalytic activity,
ARS-CoV NSP16 mutants were generated with single amino acidchanges at K46A, D130A, and K170A (Menachery et al., 2014b). All
three mutant viruses were viable and had no replication defects
in Vero cells, contrasting previous deletion studies in BHK cells
(Almazan et al., 2006). Underlying innate immunity may account
for these differences, as all three SARS-CoV mutants were attenu-
ated in immune competent Calu3 cells during multistep replication
cycles (MOI 0.01) (Menachery et al., 2014b). The SARS-CoV D130A
mutant, the least attenuated in Calu3 cells, was characterized fur-
ther in vivo demonstrating robust attenuation at late times (D4 and
later) in regards to weight loss, viral lung titers, lung histology,
and breathing function. Notably, SARS-CoV NSP16 attenuation
was delayed both in vitro and in vivo, suggesting that initial infec-
tion failed to stimulate a more robust immune response than WT.
While the NSP16 displayed increased type I IFN sensitivity sim-
ilar to mutants in MHV and 229E (Zust et al., 2011), the SARS-CoV
mutant virus failed to induce more type I IFN either in vitro or in vivo
(Menachery et al., 2014b). Similarly, analysis of known interferon-
stimulated genes (Menachery et al., 2014a) including IFIT1 and
MDA5 found no significant change induction magnitude or kinetics
following NSP16 challenge as compared to WT (Fig. 3A–C). Globa-
bly, the data indicates that while SARS-CoV mutants are attenuated
in vitro and in vivo, the immune response induced by the host plays
a critical role in this attenuation. Differences between the NSP16
mutants across the viral families may be explained by the base-
line immune response in the target cell, which may be in higher in
some (macrophages) and less robust in others (fibroblasts, epithe-
lial cells).
While targeting the KDKE catalytic tetrad has been the main
approach to ablate 2′O-MTase activity in a variety of CoVs, several
other approaches may also be effective in knocking out NSP16 activ-
ity. As mentioned previously, the NSP16/NSP10 complex only binds
to 0′ capped RNA, thus permitting activity; therefore, mutation to
the N7-methyl-transferase activity of NSP14 is also be expected
to ablate NSP16 and may capture similar phenotypic outcomes.
In addition, recent efforts to characterize the residues required
for NSP16/NSP10 interaction also provide another means to tar-
get 2′O-MTase function. Prior work has demonstrated that alanine
replacement of central core amino acids in MHV NSP10 resulted in
lethal phenotypes (Donaldson et al., 2006); these mutations track
within the interface of the NSP16/NSP10 complex and thus may
alter or ablate 2′O-MTase function (Decroly et al., 2011; Lugari et al.,
2010). Other approaches, including altering the substrate binding
site or taking advantage of temperature sensitive mutants, repre-
sent novel means to target and diminish 2′O-MTase activity in the
CoV family of viruses.
6. Restoration of NSP16 mutants
Sensitivity to type I IFN has been a hallmark of NSP16 mutants
across the CoV family. For HCoV 229E and MHV mutants encoding
the D to A substitution (D129A and D130A, respectively), infection
also results in augmented type I IFN production and attenuation in
macrophages (Zust et al., 2011). In contrast, while the same muta-
tion in SARS-CoV (D130A) resulted in ablated 2′O-MTase activity
and IFN sensitivity, surprisingly, infection did not augment type I
IFN induction relative to WT virus (Menachery et al., 2014b). This
fact suggests that despite producing high levels of recognizable
non-self RNA, SARS-CoV is able to control type I IFN induction path-
ways. Illustrating this point, IFNAR−/− mice have augmented viral
replication, but fail to restore virulence to NSP16 deficient SARS-
CoV. Similarly, while not restored to WT levels, the D130A mutation
in MHV results in robust replication within the liver and the spleen
of IFNAR−/− mice (Zust et al., 2011). Together, the data indicate that
while type I IFN plays a critical role, NSP16 attenuation is primarily
mediated by additional host immune responses.
Fig. 3. SARS-CoV 2′O-MTase mutant maintains similar ISG profile to WT. (A, B) Consensus interferon-stimulated gene expression (as defined in (Menachery et al., 2014a))






































T SARS-CoV expression from NSP16 mutant virus expression provides relative
erived from previous in vitro with SARS-CoV (Sims et al., 2013; Menachery et al., 20
Edgar et al., 2002) through GEO Series accession number GSE33267 and GSE33266
Contrasting type I IFN deficiency, the absence of MDA5 results
n a more robust restoration of CoV 2′O-MTase mutants. Studies
n murine macrophages demonstrated that absent MDA5, MHV
130A mutant had restored viral replication and reduced IRF3
uclear localization (Zust et al., 2011). While sensitivity to type
IFN was maintained, the results suggested that the absence of
he sensor molecule results in reduced IFN induction (Zust et al.,
011). However, MDA5−/− mice failed to have any restoration in
eplication of the MHV D130A, but had partial restoration of the
ap-0 binding mutant, MHV Y15A. When complemented with TLR7
eficiency, replication of MHV D130A was restored to IFNAR−/−
evels in vivo, suggesting that both pathways contribute to attenu-
tion of MHV 2′O-MTase mutants. In contrast, SARS-CoV D130A
utants were found to have restored virulence in MDA5−/−
ice in terms of weight loss, histology, and breathing function
Menachery et al., 2014b). This discrepancy is likely explained by
ifferences in cell tropism, as SARS-CoV is limited to ACE2 express-
ng cells within the lung; in contrast, MHV infects a variety of
mmune competent cells and likely results in more robust, sys-
emic responses. Importantly, while the absence of MDA5 restores
ARS-CoV 2′O-MTase mutants in vivo, no evidence exists to suggest
t plays an effector role. Knockdown studies utilizing shRNA indi-
ated no augmented replication for the SARS-CoV NSP16 mutant
n the absence of MDA5, contrasting IFIT family results (Fig. 4)
Menachery et al., 2014b). The results suggest that MDA5 functions
n primary recognition of CoV 2′O-MTase mutants and initiates
n interferon-stimulated gene cascade that leads to attenuation of
eplication in vitro and in vivo.
While MDA5 and type I IFN deficiency led to restoration of CoV
′O-MTase mutants, neither immune component provides direct
ffector function. Instead, the host response requires the activ-
ty of the IFIT family of proteins to mediate attenuation of CoV
SP16 mutants. For the NSP16 mutants of MHV and HCoV 229E,
he absence of IFIT1 resulted in restored replication relative to
T control in vitro (Habjan et al., 2013; Zust et al., 2011); similar
esults were seen for SARS-CoV NSP16 with both IFIT1 and IFIT2e between WT and 2′O-MTase mutant. RNA expression and proteomics data were
The raw microarray data are accessible through the NCBI Gene Expression Omnibus
knockdown (Menachery et al., 2014b). However, while replication
is augmented in IFIT1−/− mice, MHV D130A remains significantly
attenuated relative to WT MHV (Habjan et al., 2013). These results
indicate that both IFIT restriction and type I IFN induction via
MDA5/TLR7 contribute to attenuation to MHV 2′O-MTase mutants.
In contrast, the SARS-CoV NSP16 mutant was restored to near WT
levels in IFIT1−/− mice (Menachery et al., 2014b); in terms of viral
replication, weight loss, and breathing function, IFIT1 deficiency
resulted in robust infection with the 2′O-MTase mutant and only
modest augmentation of WT SARS-CoV. These results are consistent
with restored virulence observed with WNV 2′O-MTase mutants in
IFIT1−/− mice (Daffis et al., 2010) and indicate that IFIT1 mediates
primary attenuation of SARS-CoV 2′O-MTase mutant. To date, nei-
ther CoV mutant has been tested in IFIT2−/− mice which display
increased sensitivity to neurotropic viruses including wild-type
MHV and VSV (Butchi et al., 2014; Fensterl et al., 2014). Similar
to the MDA5 deficiency, differences in cell type and tissue tropism
between MHV and SARS-CoV likely contribute to differential 2′O-
MTase mutant restoration in IFIT1−/− deficient hosts.
The robust attenuation of CoV 2′O-MTase mutants highlights the
importance of specific aspect of the host innate immune response
in limiting virus infection. The absence of both type I IFN induc-
tion through MDA5/TLR7 and subsequent ISG effector responses
through the IFIT family are necessary components in restoration
of CoV NSP16 mutants. Notably, the presence of the functional
NSP16 and other viral antagonists rendered these innate immune
pathways ineffective against WT viruses, as noted by minimal aug-
mentation of disease in IFNAR−/−, MDA5−/− or IFIT1−/− KO mice
(Frieman et al., 2010; Habjan et al., 2013; Menachery et al., 2014b).
The results also suggest that the rapid and robust innate mediated
attenuation observed with CoV NSP16 mutants may preclude the
necessity for an adaptive immune response for clearance. While
prior work had demonstrated a requirement for both B and T-cells
in clearance of both WT and SARS-CoV mutants (Graham et al.,
2012; Sheahan et al., 2008), the presence of functional MDA5 and
IFIT1 might be sufficient to clear SARS-CoV NSP16 without an
Fig. 4. IFIT proteins, not MDA5, provide effector function against NSP16 mutant
viruses. Vero cells expressing shRNA (as described in (Menachery et al., 2014b))
targeting IFIT1 (blue), IFIT2 (red), MDA5 (green, two constructs) or no shRNA control
(black) were pretreated with IFN (PBL Laboratories) and infected with (A) SARS-

























Fig. 5. Adaptive immune response still required for NSP16 clearance. Ten-week-
old mice deficient in adaptive immunity (RAG−/−) were infected with either
SARS-CoV MA15 (black) or NSP16 (red). (A) Weight loss and (B) viral titer results
demonstrate continued attenuation of NSP16, but failed clearance of the either
virus ten day post-infection. This study was carried out in accordance with the
recommendations for care and use of animals by the Office of Laboratory Ani-
mal Welfare (OLAW), NIH. The UNC Institutional Animal Care and Use Committee
(IACUC) (UNC, Permit Number A-3410-01) approved the animal study protocol
host immune response (Ma et al., 2014).<0.05, **<0.01, ***<0.001.
dditional adaptive response. To test this theory, RAG−/− deficient
ice were infected with either WT SARS-CoV or SARS-CoV NSP16
Fig. 5). The results demonstrated that while attenuation was simi-
ar in regards to weight loss, replication of SARS-CoV NSP16 was
aintained through day 10 with no significant difference relative
o WT SARS-CoV. Together, the results indicate that despite innate
ediated attenuation, SARS-CoV 2′O-MTase mutants still require
n adaptive immune response for sterilizing immunity and clear-
nce.
. 2′O-MTase based therapeutic development
Having identified the host processes that mediate 2′O-MTase
utant attenuation, the possibility exists to leverage this knowl-
dge for the development of therapeutic treatment options for
uman disease. While more standard treatments target essential
iral processes like viral proteases or replication complexes forma-
ion, this approach impairs aspects of viral infection that improve
he efficacy of the host immune response. By targeting and dis-
upting 2′O-MTase activity, viral mRNAs become susceptible to the
ctivities of MDA5 and IFIT family members, attenuating viral infec-
ion through natural innate immune responses. Importantly, the
road conservation of 2′O-MTase in CoVs, as well as in a number of
ther viral families, provides a broadly applicable approach ideal
or targeting both current and emerging viral infections. With this
n mind, both vaccine and drug treatment approaches have been(IACUC #13-033) followed in this experiment.
conceived to target 2′O-MTase activity for CoVs and other emergent
viral infections.
7.1. 2′O-MTase based vaccines
Employing 2′O-MTase mutants as a live attenuated vaccine plat-
form has proved effective in developing vaccine strategies for a
variety of viral families. Several flaviviruses including West Nile,
Dengue, and Japanese Encephalitis viruses have utilized mutation
in the 2′O-MTase active domain of NS5 to attenuate and protect
animals from lethal challenge (Dong et al., 2008; Zust et al., 2013).
A similar vaccination approach has recently been described for
paramyxoviruses including human metapneumovirus and targets
the L protein which mediates 2′O-MTase activity (Zhang et al.,
2014). In addition, recent work with Venezuelan Equine Encephali-
tis virus (VEE) revealed a single nucleotide mutation in the 5′UTR
of the vaccine strain that ablated the RNA structure that mim-
icked 2′O-Methylations and allowed recognition of viral RNA by
IFIT1 (Hyde et al., 2014). The broad efficacy of the approach across
a variety viral families lends credence to application to CoVs and
other emerging viruses that employ 2′O-MTase to overcome theParalleling the success found for other RNA virus vaccines, the
2′O-MTase mutant of SARS-CoV proved effective as a live attenu-































































Fig. 6. Targeting 2′O-MTase activity effective in the context of IFN response. WT
SARS-CoV replication following pretreatment of Vero cells with either of IFNalb/C mice (10 week old) were inoculated with 100pfu of SARS-
oV NSP16 or PBS mock control; following challenge with a lethal
ose of mouse-adapted SARS-CoV (MA15 1 × 105), mock vacci-
ated animals endured rapid weight loss and death. In contrast,
NSP16 vaccinated animals presented no clinical signs of disease
nd survived the lethal challenge. Importantly, plaque reduction
eutralization titers (PRNT50) indicated a very high level of protec-
ive antibody (>1:1600) produced following NSP16 vaccination.
his PRNT50 value represents an improvement over other live
ttenuated platforms (Fett et al., 2013; Graham et al., 2012) and
upports the idea that the more robust replication induced early
uring NSP16 infection may improve the overall immune perfor-
ance (Fett et al., 2013; Menachery et al., 2014b). Alternatively,
he augmented IFN induction via MDA5 may result in a greater
H1 skew thus improving the quality of the protective adaptive
esponse. Supporting this idea, MDA5 deficiency has been reported
o alter the early inflammatory response in the lung following
endai virus infection (Kim et al., 2014); decreased neutrophil
nd increased alternatively activated macrophage populations are
ndicative of altered T-cell composition and may impact immune
emory response (Page et al., 2012). While further testing is
equired, the results suggest that targeting 2′O-MTase activity via
accine may serve dual roles of both attenuating the virus and
mproving the overall immune response.
While initial studies are promising, several significant questions
emain to be addressed in regards to the efficacy and utility of a
NSP16-based vaccine platform. First among them is the ability
f this mutant to protect aged animals. To date, multiple vac-
ine platforms have failed or caused immune induced pathology
n aged populations. While live attenuated SARS-CoV platforms
ave had greater efficacy (Bolles et al., 2011; Sheahan et al., 2011),
hese protection parameters must be explored in the context of
he senescent host for any NSP16-based vaccine to move for-
ard. In addition, while the D130A mutation has been maintained
n tissue culture, more studies are required to assess the possibil-
ty of reversion of the two nucleotide change in vivo as previously
escribed (Graham et al., 2012); the results may indicate the need
o generate and evaluate more reversion proof mutants employing
ither a three nucleotide change or multiple mutations within the
DKE motif. Finally, like other vaccine platforms, NSP16 vacci-
ation must evaluate efficacy against heterologous challenge with
otential emergent SARS-like CoV strains including newly discov-
red bat strains (Ge et al., 2013; He et al., 2014). Despite these
uestions, utilizing 2′O-MTase mutation as the basis for a live atten-
ated CoV platform has great promise for not only SARS-CoV, but
ther emergent viruses like MERS-CoV and PEDV.
.2. Drug targeting CoV 2′O-MTase activity
In addition to the vaccine platform, efforts to impair 2′O-MTase
ctivity in the context of a normal wild-type infection may also
rovide an effective treatment option. Over the years, a number
f small molecules have been identified for their ability to inhibit
he activity of CoV NSP16 including S-adenosyl-l-homocysteine,
inefungin, and aurintricarboxylic acid (ATA) (Bouvet et al., 2010;
ecroly et al., 2011; He et al., 2004). These molecules, all believed
o interfere with substrate binding, effectively ablated 2′O-MTase
ctivity of both NSP16/NSP10 and NSP14 (Bouvet et al., 2010). Given
he robust attenuation of 2′O-MTase mutants, this finding provided
mechanistic explanation for ATA inhibition of SARS-CoV replica-
ion that was previously described (He et al., 2004). In contrast,
inefungin pretreatment alone proved ineffective in significantly
educing SARS-CoV replication (Fig. 6); however, in the context of
ype I IFN induction the addition of sinefungin improved the overall
nhibition. Collectively, the data suggest that 2′O-MTase inhibition
an be used as a CoV treatment, but requires the activation of the(100 units/mL), sinefungin (2.56 mM), or combination of both 16 h prior to infec-
tion. Viral replication evaluated 24 h post-infection. P-values based on Student’s
T-test and are marked as indicated: *<0.05, ***<0.001.
ISG response for efficacy. Notably, targeting the SAM-binding site
would also be expected to work against other virally encoded 2′O-
MTase providing a broad based antiviral therapeutic. However, the
impact on host 2′O-MTase activity may induce cytotoxic effects that
limit its utility. Overall, the data argues that targeting 2′O-MTase
via the SAM-binding site remains a viable treatment approach but
requires further refinement and testing.
In addition to targeting the 2′O-MTase active site, other
approaches exploit indirect factors necessary for NSP16 activity.
As highlighted earlier, NSP16 requires binding with NSP10 for sta-
bility and 2′O-MTase activity (Bouvet et al., 2010). Therefore, drugs
that interfere with this interaction may prove to be an effective
treatment strategy for SARS and other CoVs. Illustrating this point,
two short peptides derived from the interaction domains of SARS-
CoV NSP10 have been shown to ablate NSP16 2′O-MTase activity
(Ke et al., 2012). The inverse approach, designing peptides based on
the NSP16 binding domain, may also provide an additional avenue
for therapy. In both cases, disruption of NSP10/NSP16 interaction
should attenuate the wild-type virus if a robust type I IFN/ISG
response has been induced. Similarly, the sequential nature of CoV
capping (Fig. 1) requires recognition of upstream modifications
for activity. Therefore, disrupting elements of N7-methyl capping
via NSP14 or other CoV mRNA process should also ablate NSP16
activity, thus rendering enhanced susceptibility. These CoV specific
approaches have the potential to significantly impact viral infec-
tion and have minimal toxicity concerns compared to approaches
that target the 2′O-MTase active site. Importantly, all of the drug
approaches outlined require induction of the host ISG response for
efficacy and may vary greatly depending on the IFN antagonists
encoded by the specific CoV in question.
8. Conclusion and future directions
Together, the studies of NSP16 have defined the critical elements
and illustrated the importance of 2′O-MTase activity for successful
coronavirus infection. In the absence of functional NSP16, SARS-
CoV, HCoV 229E, and MHV infections are significantly attenuated
both in vitro and in vivo. This deficit is mediated by both increased
recognition of viral RNA by host sensor molecules as well as
the effector responses of the IFIT family of ISGs. Understanding
these precise viral/host interactions permits the development of

































fficacy of the existing host immune response. Contrasting methods
hat target viral specific factors like replication, fidelity, or struc-
ural protein function, the approach has broad application potential
o not only CoVs, but other viral families that employ 2′O-MTase
pproaches to capping viral RNA. Importantly, with the continued
hreat of viral emergence highlighted by MERS-CoV and PEDV in
he past few years, targeting the highly conserved NSP16 activity
rovides a therapeutic approach applicable to any novel CoV. While
ignificant research questions remain, the understanding and tar-
eting of 2′O-MTase activity represents an important avenue for
reating current and future CoV mediated diseases.
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